KDR and cancer: Angiogenesis inhibitors, such as bevacizumab, can face resistance from cancer cells that involves alteration of VEGF tyrosine kinase receptors (VEGFR) and binding with Neuropilin-1 (NP1) and/or Neuropilin-2 (NP2) [151,152].